For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | -518,168 | 697,723 | 3,785,649 | 3,975,522* |
| General and administrative | 1,687,403 | 2,126,918 | 1,867,040 | 1,719,467.5* |
| Restructuring costs | 42,414 | 1,236,172 | - | - |
| Total operating expenses | 1,211,649 | 4,060,813 | 5,652,689 | 5,694,989.5* |
| (loss) income from operations | -1,211,649 | -4,060,813 | -5,652,689 | -13,539,614* |
| Interest income, net | 186,171 | 167,311 | 141,996 | 101,464* |
| (loss) gain on foreign currency transactions | -291,522 | -135,659 | -61,735 | -1,618,666.5* |
| Research and development incentive award | -341,951 | -478,959 | - | 151,604* |
| Gain (loss) on fair value adjustments | 435,193 | 5,379,500 | -4,368,869 | 496,570* |
| Total other income (expense) | 671,793 | 5,890,111 | -4,288,608 | -1,172,236.5* |
| (loss) income before income taxes | -539,856 | 1,829,298 | -9,941,297 | -14,711,850.5* |
| Income tax benefit | -34,793 | -34,794 | -34,793 | -364,000.5* |
| Net (loss) income | -505,063 | 1,864,092 | -9,906,504 | -14,347,850* |
| Unrealized gain (loss) on foreign currency translation | 157,897 | 570,580 | 49,221 | 2,394,905.5 |
| Total other comprehensive income (loss) | 157,897 | 570,580 | 49,221 | 2,394,905.5* |
| Total comprehensive income (loss) | -347,166 | 2,434,672 | -9,857,283 | -11,952,944.5 |
| Basic EPS | -0.09 | 0.41 | -4.41 | -7.592 |
| Diluted EPS | -0.09 | -0.77 | -4.41 | -7.592 |
| Basic Average Shares | 5,411,244 | 4,536,235 | 2,246,066 | 1,574,455 |
| Diluted Average Shares | 5,411,244 | 4,536,235 | 2,246,066 | 1,574,455 |
Neuphoria Therapeutics Inc. (NEUP)
Neuphoria Therapeutics Inc. (NEUP)